Alterations in endothelial nitric oxide synthase activity and their relevance to blood pressure
T Suvorava, S Metry, S Pick, G Kojda - Biochemical pharmacology, 2022 - Elsevier
Among all physiologic functions of nitric oxide (NO) known so far, NO-dependent regulation
of vascular tone is one of the most important. Under physiological conditions vascular NO is …
of vascular tone is one of the most important. Under physiological conditions vascular NO is …
Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis
M Li, T Yi, F Fan, L Qiu, Z Wang, H Weng, W Ma… - Cardiovascular …, 2022 - Springer
Background Recent studies have shown that sodium-glucose cotransporter-2 inhibitors
(SGLT2i) can achieve significant improvement in blood pressure in people with diabetes …
(SGLT2i) can achieve significant improvement in blood pressure in people with diabetes …
Advances in the treatment strategies in hypertension: present and future
P Verdecchia, C Cavallini, F Angeli - Journal of cardiovascular …, 2022 - mdpi.com
Hypertension is the most frequent chronic and non-communicable disease all over the
world, with about 1.5 billion affected individuals worldwide. Its impact is currently growing …
world, with about 1.5 billion affected individuals worldwide. Its impact is currently growing …
Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review
X Lingli, X Wenfang - Life Sciences, 2022 - Elsevier
Metabolic diseases, such as diabetes, gout and hyperlipidemia are global health
challenges. Among them, diabetes has been extensively investigated. Type 2 diabetes …
challenges. Among them, diabetes has been extensively investigated. Type 2 diabetes …
The therapeutic role of SGLT-2 inhibitors in acute heart failure: from pathophysiologic mechanisms to clinical evidence with pooled analysis of relevant studies across …
(1) Background: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors constitute a novel
drug class with remarkable cardiovascular benefits for patients with chronic heart failure …
drug class with remarkable cardiovascular benefits for patients with chronic heart failure …
Review of SGLT2i for the treatment of renal complications: experience in patients with and without T2D
O González-Albarrán, C Morales, M Pérez-Maraver… - Diabetes Therapy, 2022 - Springer
The management of type 2 diabetes (T2D) involves decreasing plasma glucose levels and
reducing cardiovascular and microvascular complications. Diabetic kidney disease (DKD) …
reducing cardiovascular and microvascular complications. Diabetic kidney disease (DKD) …
Sodium glucose cotransporter-2 inhibitors: spotlight on favorable effects on clinical outcomes beyond diabetes
V Čertíková Chábová, O Zakiyanov - International Journal of Molecular …, 2022 - mdpi.com
Sodium glucose transporter type 2 (SGLT2) molecules are found in proximal tubules of the
kidney, and perhaps in the brain or intestine, but rarely in any other tissue. However, their …
kidney, and perhaps in the brain or intestine, but rarely in any other tissue. However, their …
Effect of empagliflozin on sphingolipid catabolism in diabetic and hypertensive rats
R Pérez-Villavicencio, J Flores-Estrada… - International Journal of …, 2022 - mdpi.com
The profile of sphingomyelin and its metabolites shows changes in the plasma, organs, and
tissues of patients with cardiovascular, renal, and metabolic diseases. The objective of this …
tissues of patients with cardiovascular, renal, and metabolic diseases. The objective of this …
Efficacy and safety of ertugliflozin in type 2 diabetes: a systematic review and meta-analysis
L Liu, FH Shi, H Xu, Y Wu, ZC Gu… - Frontiers in Pharmacology, 2022 - frontiersin.org
Objective: To evaluate the efficacy and safety of ertugliflozin in patients with type 2 diabetes.
Methods: MEDLINE, EMBASE, and Cochrane Library were searched (July 31, 2021) for …
Methods: MEDLINE, EMBASE, and Cochrane Library were searched (July 31, 2021) for …
Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD
AJ Kula - Pediatric Nephrology, 2022 - Springer
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) were originally developed as glucose-
lowering agents. These medications function by inhibiting glucose and sodium reabsorption …
lowering agents. These medications function by inhibiting glucose and sodium reabsorption …